Clinical trial
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute…
NCT00418275 · Global Biotech, Industry · Completed
Key facts
| NCT number | NCT00418275 |
|---|---|
| Title | Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke. |
| Official title | A Dose Finding, Pharmacokinetic and Safety Study of a Recombinant Human Plasminogen Activator (HTU-PA) in Patients With Acute Ischemic Stroke |
| Lead sponsor | Global Biotech, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cerebrovascular Accident |
| Intervention type | Genetic |
| Interventions | Recombinant Human Plasminogen Activator (HTUPA) |
| Enrollment | 30 |
| Start date | Apr 1, 2001 |
| Completion | Jun 1, 2004 |
| First posted | Jan 4, 2007 |
| Last update posted | Jan 4, 2007 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: